289: Other diseases of blood and blood-forming organs
289.8 Other specified diseases of blood and blood-forming organs
289.81: Primary hypercoagulable state
Activated protein C resistance
Antiphospholipid antibody syndrome
Antithrombin III deficiency
Factor V Leiden mutation
Lupus anticoagulant with hypercoagulable state
Protein C deficiency
Protein S deficiency
Prothrombin gene mutation
Systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state
Excludes:
anti-phospholipid antibody, finding without diagnosis (795.79)
anti-phospholipid antibody with hemorrhagic disorder (286.53)
lupus anticoagulant (LAC) finding without diagnosis (795.79)
lupus anticoagulant (LAC) with hemorrhagic disorder (286.53)
secondary activated protein C resistance (289.82)
secondary antiphospholipid antibody syndrome (289.82)
secondary lupus anticoagulant with hypercoagulable state (289.82)
secondary systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (289.82)
systemic lupus erythematosus [SLE] inhibitor finding without diagnosis (795.79)
systemic lupus erythematosus [SLE] inhibitor with hypercoagulable state (286.53)
289.82: Secondary hypercoagulable state
Excludes:
heparin-induced thrombocytopenia (HIT) (289.84)
289.83: Myelofibrosis
Myelofibrosis NOS
Secondary myelofibrosis
Code first the underlying disorder, such as:
malignant neoplasm of breast (174.0-174.9, 175.0-175.9)
Use additional code for associated therapy-related myelodysplastic syndrome, if applicable (238.72, 238.73)
Use additional external cause code if due to anti-neoplastic chemotherapy (E933.1)
Excludes:
idiopathic myelofibrosis (238.76)
leukoerythroblastic anemia (284.2)
myelofibrosis with myeloid metaplasia (238.76)
myelophthisic anemia (284.2)
myelophthisis (284.2)
primary myelofibrosis (238.76)
289.84: Heparin-induced thrombocytopenia (HIT)
289.89: Other specified diseases of blood and blood-forming organs
Hypergammaglobulinemia
Pseudocholinesterase deficiency

Home